{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:28:25Z","timestamp":1789687705921,"version":"4.0.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.rdc.2012.08.010","type":"journal-article","created":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T02:19:00Z","timestamp":1347589140000},"page":"523-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comorbidities in Patients with Spondyloarthritis"],"prefix":"10.1016","volume":"38","author":[{"given":"Irene E.","family":"van der Horst-Bruinsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.M.","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2012.08.010_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The assessment of Spondyloarthritis International Society Classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of the diagnostic criteria for ankylosing spondylitis; a proposal for the modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","article-title":"Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors","volume":"41","author":"Braun","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00002281-199907000-00004","article-title":"Enthesitis in ankylosing spondylitis and related spondylarthropathies","volume":"11","author":"McGonagle","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib7","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/ard.2007.084244","article-title":"Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index","volume":"68","author":"Maksymowych","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-012-2018-0","article-title":"High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review","author":"van der Weijden","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib9","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-011-1766-z","article-title":"High frequency of vertebral fractures in early spondylarthropathies","volume":"23","author":"van der Weijden","year":"2012","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ejim.2011.06.006","article-title":"Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications","volume":"22","author":"El Maghraoui","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.rdc.2012.08.010_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","article-title":"Efficacy of celecoxib, a cycloogynase-2-specific inhibitor, in the treatment of ankylosing spondylitis","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib13","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","article-title":"Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib16","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.010_bib19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Once-weekly 50-mg dosing of etanercept (Enbrel(R)) is as effective as 25-mg twice-weekly dosing in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib20","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib21","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.010_bib22","first-page":"531","article-title":"Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept","volume":"31","author":"Brandt","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.010_bib23","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.010_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.010_bib25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/ard.2004.020800","article-title":"Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study","volume":"63","author":"Tan","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.010_bib26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.010_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jbspin.2011.02.018","article-title":"Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition","volume":"79","author":"Lekpa","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.010_bib29","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","article-title":"Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study","volume":"54","author":"Braun","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib30","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept","volume":"52","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.010_bib31","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib35","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.010_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semarthrit.2008.04.004","article-title":"Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy","volume":"39","author":"Barnabe","year":"2009","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.010_bib38","first-page":"2226","article-title":"Prevalence of the spondyloarthritides in patients with uveitis","volume":"31","author":"Linder","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib39","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2003.07.011","article-title":"Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases","volume":"111","author":"Monnet","year":"2004","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.010_bib40","first-page":"2198","article-title":"Undiagnosed spondyloarthropathy in\u00a0patients presenting with anterior uveitis","volume":"27","author":"Pato","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.010_bib41","first-page":"2568","article-title":"The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27","volume":"32","author":"Linssen","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib42","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period","volume":"30","author":"Munoz-Fernandez","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.010_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/09273948.2010.542269","article-title":"What is new HLA-B27 acute anterior uveitis?","volume":"19","author":"Wakefield","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.010_bib44","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.010_bib45","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.010_bib47","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.20754","article-title":"Effect of etanercept on iritis in patients with ankylosing spondylitis","volume":"50","author":"Rosenbaum","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.010_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.010_bib49","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib50","first-page":"630","article-title":"Decreased recurrence rate of uveitis in ankylosing spondylitis treated with adalimumab-an interim analysis","volume":"28","author":"van der Horst-Bruinsma","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib51","first-page":"1161","article-title":"Clinical features of ankylosing spondylitis","volume":"vol. 2","author":"Khan","year":"2003"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.010_bib52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.010_bib53","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.010_bib54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.010_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/rheumatology\/27.2.163-b","article-title":"Ileocolonoscopy and spondarthritis","volume":"27","author":"Mielants","year":"1988","journal-title":"Br J Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2012.08.010_bib56","first-page":"1542","article-title":"Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic, and genetic features in relation to the type of histology. A prospective study","volume":"18","author":"Mielants","year":"1991","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2012.08.010_bib57","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3899\/jrheum.100269","article-title":"pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease","volume":"37","author":"de Vries","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2012.08.010_bib58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib59","first-page":"S67","article-title":"Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs","volume":"20","author":"van der Horst-Bruinsma","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2012.08.010_bib60","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9317","key":"10.1016\/j.rdc.2012.08.010_bib61","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.rdc.2012.08.010_bib62","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.rdc.2012.08.010_bib63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.010_bib64","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.rdc.2012.08.010_bib65","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.rdc.2012.08.010_bib66","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2007.02.004","article-title":"The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia","volume":"28","author":"Hahn","year":"2007","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.rdc.2012.08.010_bib68","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib69","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.30277","article-title":"Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib70","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","article-title":"Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis","volume":"34","author":"Peters","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"4 Suppl 55","key":"10.1016\/j.rdc.2012.08.010_bib71","first-page":"S127","article-title":"Mortality in rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Zochling","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl","key":"10.1016\/j.rdc.2012.08.010_bib72","first-page":"S477","article-title":"Men with ankylosing spondylitis have an increased risk of myocardial infarction","volume":"50","author":"Symmons","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib73","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/art.30581","article-title":"Increased risk of cardiovascular and cerebrovascular disease in individuals with ankylosing spondylitis: a population-based study","volume":"63","author":"Szabo","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib74","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/ard.2009.110593","article-title":"Ankylosing spondylitis; a risk factor for myocardial infarction?","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib75","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr.20408","article-title":"Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis","volume":"63","author":"Bremander","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.010_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2377-12-41","article-title":"Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden","volume":"12","author":"Z\u00f6ller","year":"2012","journal-title":"BMC Neurol"},{"key":"10.1016\/j.rdc.2012.08.010_bib77","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MD.0b013e3181c10773","article-title":"The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease","volume":"88","author":"Gonzalez-Juanatey","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2012.08.010_bib78","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3899\/jrheum.110792","article-title":"Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis","volume":"9","author":"Hamdi","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib79","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jbspin.2010.11.003","article-title":"Aortitis and periaortitis in ankylosing spondylitis","volume":"78","author":"Palazzi","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rdc.2012.08.010_bib80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10067-005-1117-6","article-title":"Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population?","volume":"25","author":"Brunner","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2012.08.010_bib81","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4250\/jcu.2012.20.1.30","article-title":"Early cardiac valvular changes in ankylosing spondylitis: a transesophageal echocardiography study","volume":"20","author":"Park","year":"2012","journal-title":"J\u00a0Cardiovasc Ultrasound"},{"key":"10.1016\/j.rdc.2012.08.010_bib82","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00002281-199002040-00005","article-title":"Cardiac, ocular, and renal manifestations of seronegative spondylarthropathies","volume":"2","author":"Youssef","year":"1990","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib83","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/ard.50.6.348","article-title":"Heart conduction disturbance: an HLA-B27 associated disease","volume":"50","author":"Peeters","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-002-8271-x","article-title":"Echocardiographic evidence of cardiac involvement in ankylosing spondylitis","volume":"21","author":"Yildirir","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/03009740903096101","article-title":"The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis","volume":"39","author":"Dik","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib86","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.atherosclerosis.2006.11.003","article-title":"Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis","volume":"196","author":"Caliskan","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.rdc.2012.08.010_bib87","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.remn.2010.12.002","article-title":"Left ventricular wall function abnormalities in patients with ankylosing spondylitis evaluated by gated myocardial perfusion scintigraphy","volume":"30","author":"Yalcin","year":"2011","journal-title":"Rev Esp Med Nucl"},{"key":"10.1016\/j.rdc.2012.08.010_bib88","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib89","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/ard.2009.116178","article-title":"Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study","volume":"69","author":"Kang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib90","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/acr.20364","article-title":"Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis","volume":"63","author":"Mathieu","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2012.08.010_bib91","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/CS20040326","article-title":"Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation","volume":"109","author":"Divecha","year":"2005","journal-title":"Clin Sci"},{"key":"10.1016\/j.rdc.2012.08.010_bib92","first-page":"292","article-title":"High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNF alpha treatment: correlation with disease activity","volume":"27","author":"Papadakis","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib93","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2012.08.010_bib94","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/HYPERTENSIONAHA.109.143982","article-title":"Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study","volume":"55","author":"Angel","year":"2010","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.rdc.2012.08.010_bib95","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajh.2012.12","article-title":"Effect of 1-Year anti-TNF-\u03b1 therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study","volume":"25","author":"Angel","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.rdc.2012.08.010_bib96","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/ard.2007.086777","article-title":"Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade","volume":"68","author":"van Eijk","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib97","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10067-010-1402-x","article-title":"Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade","volume":"29","author":"Syngle","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib98","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2310\/JIM.0b013e3182330720","article-title":"Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis","volume":"59","author":"Senel","year":"2011","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.rdc.2012.08.010_bib99","first-page":"2440","article-title":"Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab","volume":"33","author":"Spanakis","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib100","first-page":"921","article-title":"Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Kiortsis","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.010_bib101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jbspin.2009.05.012","article-title":"Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis","volume":"77","author":"Mathieu","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rdc.2012.08.010_bib102","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.24492","article-title":"Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis","volume":"60","author":"van Eijk","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.010_bib103","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM199805213382106","article-title":"The treatment of unrelated disorders in patients with chronic medical diseases","volume":"338","author":"Redelmeier","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2012.08.010_bib104","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.010_bib105","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:10:47Z","timestamp":1760181047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X12000695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0889857X12000695"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.010","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities in Patients with Spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}